This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Series

Goran Forsberg, PhD
Chief Executive Officer at Cantargia AB


Göran Forsberg has been CEO for Cantargia AB since 2014. Cantargia develops antibodies for the treatment of
cancer and autoimmunity/inflammatory diseases. The lead project, CAN04, is in phase I/IIa clinical
development focused on non-small cell lung cancer and pancreatic cancer. Dr Forsberg has a PhD in
biochemistry Royal Institute of Technology, Stockholm, Sweden, is an associate professor and author of over 40
scientific publications. Previous positions include KabiGen, Pharmacia, Active Biotech and University of